- Home
- SACH vs ICCC Comparison
SACH vs ICCC Comparison
Compare SACH & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- ICCC
- Stock Information
- Founded
- SACH 2010
- ICCC 1982
- Country
- SACH United States
- ICCC United States
- Employees
- SACH N/A
- ICCC N/A
- Industry
- SACH Real Estate Investment Trusts
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- ICCC Health Care
- Exchange
- SACH Nasdaq
- ICCC Nasdaq
- Market Cap
- SACH 47.8M
- ICCC 48.3M
- IPO Year
- SACH 2017
- ICCC 1987
- Fundamental
- Price
- SACH $1.00
- ICCC $5.50
- Analyst Decision
- SACH Hold
- ICCC
- Analyst Count
- SACH 3
- ICCC 0
- Target Price
- SACH $2.25
- ICCC N/A
- AVG Volume (30 Days)
- SACH 412.5K
- ICCC 39.3K
- Earning Date
- SACH 05-01-2025
- ICCC 05-14-2025
- Dividend Yield
- SACH 17.82%
- ICCC N/A
- EPS Growth
- SACH N/A
- ICCC N/A
- EPS
- SACH N/A
- ICCC N/A
- Revenue
- SACH N/A
- ICCC $26,493,169.00
- Revenue This Year
- SACH N/A
- ICCC N/A
- Revenue Next Year
- SACH N/A
- ICCC N/A
- P/E Ratio
- SACH N/A
- ICCC N/A
- Revenue Growth
- SACH N/A
- ICCC 51.63
- 52 Week Low
- SACH $0.96
- ICCC $3.34
- 52 Week High
- SACH $3.31
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- SACH 41.11
- ICCC 59.13
- Support Level
- SACH $0.98
- ICCC $4.63
- Resistance Level
- SACH $1.06
- ICCC $5.72
- Average True Range (ATR)
- SACH 0.08
- ICCC 0.42
- MACD
- SACH -0.01
- ICCC 0.05
- Stochastic Oscillator
- SACH 17.33
- ICCC 79.82
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.